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It has been 29 years since the first prospective tri-
als of HLA matching in kidney transplantation began (1) 
with the logical assumption that results could be thereby 
improved. Except for the identification of histocompatible 
siblings as "special" donors, a matching effect was not 
evident (2). This conclusion breathed life into the still 
struggling fields of liver and heart transplantation in which 
patients could not be supported by artificial organs while 
waiting for a well-matched donor. Since then, trans-
plant surgeons have continued to claim that HLA match-
ing does not accurately predict the outcome of cadaver 
kidney transplantation (3-5) or of transplantation of ex-
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tra-renal organs including the liver (6,7). The fact that 
thousands of conflicting reports have not brought this 
controversy to a close, beyond a consensus that there 
has been a small improvement in outcome with the un-
common perfect HLA match (8), means that other fac-
tors must be sought. 
In the meanwhile, it was immediately obvious that 
a perfect or near perfect match is a supreme determi-
nant of success for bone marrow transplantation (9,10). 
A plausible explanation for this dichotomy has been pro-
vided by the recent discovery that leukocytes migrate 
perioperatively from transplanted whole organs to widely 
distributed recipient tissues where 
they can be identified many years 
later (11-13). The leukocytes leav-
ing the graft are replaced by recipi-
ent cells moving in the opposite di-
rection. The events under immu-
nosuppression, leading eventually 
to the chimerism in the graft as well 
as ubiquitously in the recipient, im-
ply that there is a mutual engage-
ment, activation, and ultimately in-
activation of the immunocytes of 
both parties. The cell mixture can 
be seen as an in vivo two-way 
mixed lymphocyte reaction (MLR) 
(Fig. 1). Such a cell interaction 
cannot transpire after bone marrow 
transplantation because the condi-
tioning cytoablation of the recipi-
ent with irradiation or myelotoxic 
Figure 1. The mutual engagement of migratory tissue 
leukocytes from the graft with those of the recipient. 
Although the potential exists for graft versus host (GVH) 
disease reactions, this rarely is evident with leukocyte-
poor organs like the kidney. HVG-host versus graft. 
drugs eliminates host hematopoi-
etic cells. Thus, the conditions in 
the bone marrow patient who can 
stimulate but not respond immu-
nologically resemble a one-way 
MLR. 
424 CURRENT OPINIONS: HLA TYPING 
We believe that the migration from organ allografts 
of donor leukocytes and their ubiquitous persistence in 
recipient tissues is the seminal explanation for allograft 
acceptance and the first stage in the development of 
donor-specific nonreactivity (tolerance) (11-13). In a 
direct extension of this concept (14), we augmented the 
naturally occurring leukocyte migration in 16 uncondi-
tioned and randomly matched recipients by infusing them 
with 3x10B/kg donor bone marrow cells on the day of 
cadaveric renal (n=9), liver (n=6). and heart (n=1) trans-
plantation. Using standard FK506-prednisone immu-
nosuppression, all 16 have good whole-organ function 
3 to 13 months later, and all have easily demonstrable 
chimerism of blood mononuclear leukocytes in the 0.5-
5% range. Although rejection was diagnosed in 9 (56%) 
of the 16 cases, this was easily treated. Trivial skin 
Match 
graft- versus-host-disease (GVHD) in 2 (12.5%) patients 
regressed without therapy. Sustained donor-specific hy-
peractivity as early as 40 days postoperatively was de-
monstrable with in vitro tests in the majority of recipi-
ents, and, in all but one, antidonor reactivity assessed 
with MLR was less than third party. 
The ultimate donor-specific nonreactivity which may 
or may not require continued immunosuppression in the 
circumstances of whole organ transplantation (12.13.15) 
with or without leukocyte augmentation is not only of 
the recipient immunocytes to the donor antigens but also 
the other way round. This is exemplified by the rarity of 
GVHD in chimeric recipients of intestinal (16) and liver 
grafts (12) that contain a dense migratory leukocyte com-
ponent. With each further day under the protective um-
brella of effective immunosuppression, a corollary ex-
pectation is that the responsible donor-
versus-recipient interactions, also gov-
erned initially by rules of histocompat-
ibility, are influenced by a kind of "mu-
tual natural immunosuppression." Here, 
each increased level of incompatibility 
provokes countervailing increases in the 
variably cancelling donor-versus-recipi-
ent and recipient-versus-donor cell reac-
tivity (Fig. 2). If the initial storm can be 
weathered, as has been increasingly 
possible with modern immunosuppres-
sion, the anticipated typing effect will 
dwindle. 
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This bidirectional censoring of his-
tocompatibility effect has been studied 
in rats (17) and particularly in mice (18), 
within which species permanent survival 
of liver allografts and their disseminated 
nonparenchymal (chimeric) cells is the 
rule without immunosuppression across 
a full range of MHC disparities. We have 
suggested that, in this process of cen-
soring, the multiple immunobiologic 
changes that occur after organ transplan-
tation (eg. altered cytokine profiles. sup-
pressor and veto cells, enhancing anti-
Total 
Mismatch 
Figure 2. Variable cancelling of histocompatibility 
matching effect after whole-organ transplantation by 
the donor/recipient leukocyte interaction shown in 
Figure 1. RX-iatrogenic immunosuppression. 
bodies) are epiphenomena of sustained 
two-way interactions between the coex-
isting donor and recipient immunocyte 
populations (11,19). 
The debate whether HLA matching increases kid-
ney allograft survival a little versus not at all, has sus-
tained a flood of disputatious articles since 1966. It has 
seldom been emphasized that these differences, even 
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when they are thought to be significant, are trivial com-
pared to the large number of badly matched kidneys 
that do well. The two-way paradigm of mixed chimer-
ism presented here provides an explanation. 
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